**Wednesday, 28 June 2017**

12:30

Expert discussion (by invitation only)   
*Scientific Committee and Selected Experts*

13:30

Concurrent lunch mini-symposia begin

14:30

Concurrent lunch mini-symposia adjourn

**Session I: Opening, Selected Abstracts, and Opening Lectures**

14:45

Welcome and Introduction

14:50

Presentation of selected abstracts

15:15

**Opening Lecture:** The role of the microbiome in cancer medicine   
*Speaker invited*

**Session II: Cancer of the Pancreas and Bile Ducts**

16:10

Clinical implications of the progress in understanding the biology of pancreatic cancer   
*Speaker invited*

16:30

Screening in familial and hereditary pancreatic cancer   
*Margaret A. Tempero, MD*

16:45

Presentation of selected abstract

16:55

Is adjuvant or neo-adjuvant treatment for pancreatic cancer the way to go?   
*Speaker invited*

17:25

Diagnostic modalities for defining resectability (CT, EUS, MRI)   
*Speaker invited*

17:45

Presentation of selected abstracts

18:05

Improving the outcome of patients with metastatic pancreatic cancer   
*Speaker invited*

18:25

New agents/strategies on the horizon in pancreatic cancer   
*Philip A. Philip, MD, PhD, FRCP*

18:45

Adjourn

19:00

Concurrent evening non-profit symposia begin

20:30

Concurrent evening non-profit symposia adjourn

20:30

Welcome reception

**Thursday, 29 June 2017**

7:00

Concurrent industry breakfast lectures begins

7:45

Concurrent industry breakfast lectures adjourn

**Session III: Meet the Expert Concurrent Presentations**

*Parallel with Session IV: Interpreting Clinical Trials Results*

08:00

Anal cancer   
*Michel Ducreux, MD, PhD and Karin Haustermans, MD, PhD*

Cholangiocarcinoma and gall bladder cancer   
*Jordan D. Berlin, MD and Thomas Gruenberger, MD*

Implementation of a wait and see program for rectal cancer: Pitfalls   
*Andre D'Hoore, MD, PhD and Rodrigo Perez, MD*

Recent advances in management of GIST   
*Speaker invited*

Thrombosis and cancer   
*Mario Dicato, MD*

**Session IV: Interpreting Clinical Trials Results**

*Parallel with Session III: Meet the Expert Concurrent Presentations*

08:00

Statistical interpretation and validity of clinical trials   
*Speaker invited*

08:20

Clinical interpretation and validity of clinical trials: When do they become practice changing?   
*Alberto Sobrero, MD*

08:40

How relevant are the ESMO and ASCO clinical benefit scales: Do they impact our practice?   
*Fortunato Ciardiello, MD, PhD*

09:10

Biosimilars: How much evidence do we need?   
*Mario Dicato, MD*

**Session V: Esophageal and Gastric Cancers**

09:00

Managing early esophageal cancer endoscopically   
*Speaker invited*

09:20

Minimally invasive surgery for cancer of the esophagus   
*Christophe Mariette, MD, PhD*

09:40

New evolutions for the neo-adjuvant and adjuvant treatment of esophageal cancer   
*Florian Lordick, MD, PhD*

10:00

Presentation of selected abstract

10:10

Gastric carcinogenesis of gastric cancer through the eyes of a pathologist   
*Fatima Carneiro, MD, PhD*

10:30

**Keynote Lecture 1:** Progress in unraveling the molecular taxonomy in gastric cancer   
*Patrick Tan, MD, PhD*

11:00

Break and poster viewing  
*Posters to be presented: Clinical/basic non-CRC abstracts  
Poster discussion guided tours*

**Session VI: Gastric Cancer**

11:30

Neo-adjuvant/Adjuvant treatment in gastric cancer: What is optimal approach in 2017? Case based discussions   
*Ian Chau, MD*

11:50

Presentation of selected abstracts

12:20

Metastatic gastric cancer: What are the indications and what is the impact of targeting the HER2 pathway?   
*Andrés Cervantes, MD, PhD*

12:30

Metastatic gastric cancer: What are the indications and what is the impact of angiogenesis inhibitors?   
*Speaker invited*

12:40

Metastatic gastric cancer: What are the indications and what is the impact of check-point inhibitors?   
*Kohei Shitara, MD*

12:50

Metastatic gastric cancer: What are the indications and what is the impact of stem-cell inhibition   
*Julien Taieb, MD*

13:10

Session adjourns

13:30

Concurrent luncheon symposia begin

15:00

Concurrent luncheon symposia adjourn

**Session VII: Frequently Asked Clinical Questions/Challenges**

15:10

Hepatitis B and C testing and treatment of flare up in GI oncology   
*Speaker invited*

15:30

IBD related GI cancers: Are they different?   
*Speaker invited*

15:45

How to do MSI testing?   
*Pierre Laurent-Puig, MD, PhD*

16:00

When and how do go BRCA testing in GI cancer and what are the implications?   
*Judith Balmaña, MD, PhD*

16:20

Presentation of selected abstracts

16:50

Break and poster viewing   
*Posters to be presented: Clinical/Basic non-CRC abstracts*

**Session VIII: Rare Tumors: Neuroendocrine Tumors and hepatocellular Cancer**

17:20

**Controversy debate:** Targeted agents versus PRRT in NET: Case scenarios

Targeted agents first   
*Speaker invited*

PRRT first   
*Jonathan Strosberg, MD*

17:50

Pathological classification of NET   
*Aurel Perren, MD*

18:10

**Controversy debate:** Hepatocellular carcinoma: Case scenarios

Medical treatment first:  
*Jordi Bruix, MD*

Locoregional treatment first   
*Michel Ducreux, MD, PhD*

18:40

New targets and new agents in HCC   
*Speaker invited*

19:00

Adjourn

19:15

Concurrent evening symposia begin

20:45

Concurrent evening symposia adjourn

**Friday, 30 June 2017**

**Session IX: Meet the Expert Concurrent Presentations**

*Parallel with Session X: Presentation of Selected Abstracts: Colorectal Cancer, Session XI: Presentation of Selected Abstracts: Miscellaneous, and Session XII: ESMO Session: Focus on Young Medical Oncologists*

08:00

Carcinoma of unknown origin   
*George Pentheroudakis, MD*

Teaching the basics of radiotherapy: IMRT, SBRT, protontherapy   
*Karin Haustermans, MD, PhD*

Treatment of elderly patients with GI cancer   
*Demetris Papamichael, MB, BS*

Workshop: Liver directed therapies: Radioembolisation, chemoembolization and surgery for metastatic CRC: Case based session   
*Bernard Nordlinger, MD and Julien Taieb, MD, PhD*

**Session X: Presentation of Selected Abstracts- Colorectal Cancer**

*Parallel with Session IX: Meet the Expert Concurrent Presentations, Session XI: Presentation of selected Abstracts: Miscellaneous*

08:00

Presentation of selected abstracts

09:10

Session adjourns

**Session XI: Presentation of Selected Abstracts: Miscellaneous**

*Parallel with Session IX: Meet the Expert Concurrent Presentations, Session X: Presentation of Selected Abstracts: Colorectal Cancer*

08:00

Presentation of selected abstracts

09:10

Session adjourns

**Session XII: ESMO Session: Focus on Young Medical Oncologists**

*Parallel with Session IX: Meet the Expert Concurrent Presentations, Session X: Presentation of Selected Abstracts: Colorectal Cancer, and Session XI: Presentation of Selected Abstracts: Miscellaneous*

**Part 1: Career Development**

08:00

How to develop a career path in the current panorama of GI oncology in Europe   
*Fotios Loupakis, MD*

08:20

The importance of mentorship in the European environment   
*Dirk Arnold, MD, PhD*

**Part 2: Scientific Session**

08:40

Liquid biopsies in managing CRC: Are we ready for prime time?   
*Speaker invited*

09:00

Next frontiers in BRAF therapeutics   
*Elena Elez, MD, PhD*

9:20

Session adjourns

**Session XIII: From Epidemiology to Prevention of GI Cancer**

09:15

Is the epidemiology of CRC and other GI cancers changing?   
*Speaker invited*

09:30

Recommendations for surveillance of adenomas   
*Jaroslaw Regula, MD*

09:50

Can we improve screening methods of colorectal cancer?   
*Nadir Arber, MD, MHA*

10:10

Are we understanding better the adenoma - carcinoma transition?   
*Eduardo Vilar Sanchez, MD, PhD*

10:30

Travel grant award ceremony

10:35

Break and poster viewing  
*Posters to be presented: Clinical/Basic CRC abstracts  
Poster discussion guided tours*

**Session XIV: Multimodality Therapy for Rectal Cancer**

11:05

Organ preservation in rectal cancer: How and for whom?   
*Rodrigo Perez, MD*

11:25

Advances and challenges in the surgical treatment of locally advanced rectal cancer   
*Andre D'Hoore, MD, PhD*

11:45

Defining the strategy in oligometastatic rectal cancer

The oncologists point of view   
*Dirk Arnold, MD, PhD*

The surgeon's point of view   
*Bernard Nordlinger, MD*

The radiation oncologist point of view   
*Felipe A. Calvo, MD*

12:25

Presentation of selected abstracts

13:00

Session Adjourns

13:20

Concurrent luncheon symposia begin

14:50

Concurrent luncheon symposia adjourn

**Session XV: Immune Mechanisms and Immune Therapy in GI Cancer**

15:00

Keynote Lecture 2: Understanding the relevant immune mechanisms in GI cancer   
*Pierre Coulie, MD, PhD*

15:30

The immune and stromal classification of colorectal cancer   
*Wolf H. Fridman, MD, PhD*

15:50

Molecular classification of colon cancer: New insights   
*Sabine Tejpar, MD, PhD*

16:10

Does the molecular and immunologic classifications have clinical implications in 2017?   
*Rodrigo Dienstmann, MD*

16:30

Discussion

16:40

Break and poster viewing  
*Abstracts to be presented: Clinical/Basic CRC abstracts*

**Session XVI: Molecular Biology in CRC**

17:10

How to approach the patient with a BRAF mutant tumor?   
*Speaker invited*

17:30

Acquired resistance to EGFR antibodies: How to manage?   
*Federica Di Nicolantonio, MD*

17:50

Immune therapy in CRC   
*Speaker invited*

18:00

Immune therapy in non-CRC GI cancer   
*Speaker invited*

18:10

Current status and perspectives on liquid biopsies in mCRC   
*Scott Kopetz, MD, PhD, FACP*

**Session XVII: Highlights of ASCO and ESMO GI Abstracts**

18:30

Selected abstracts: Highlights of poster discussions and posters at ESMO GI

19:00

Adjourn

**Saturday, 1 July 2017**

**Session XVIII: Colorectal Cancer: Tumor Board**

08:30

Multidisciplinary tumor board on resectable and borderline/potentially resectable liver metastases   
*Speaker invited*

09:00

Molecular and hereditary tumor board   
*Speaker invited*

**Session XIX: Colorectal Cancer**

09:30

Controversy debate: Updates on treatment algorithms in metastatic CRC in 2017

The ESMO guidelines on metastatic CRC   
*Eric Van Cutsem, MD, PhD*

NCCN guidelines   
*Alan P. Venook, MD*

Asian guidelines   
*Takayuki Yoshino, MD*

The left versus right colon cancer story: What is the truth   
*Speaker invited*

10:25

Break

10:55

Can we refine the selection for adjuvant treatment in colon cancer?   
*Aimery De Gramont, MD*

11:15

Presentation of selected abstracts

12:55

Session adjourns

13:15

Concurrent luncheon symposia begin

14:45

Concurrent luncheon symposia adjourn

**Session XX: Future of GI Oncology**

14:55

The surgeon of the future   
*Speaker invited*

15:05

The GI endoscopist in the future   
*Speaker invited*

15:15

The GI oncologist of the future   
*Speaker invited*

15:25

The radiation oncologist of the future   
*Speaker invited*

15:35

The pathologist of the future   
*Fatima Carneiro, MD*

15:45

The radiologist in the future   
*Speaker invited*

15:55

The nuclear medicine physician of the future   
*Christophe Deroose, MD, PhD*

**Session XXII: Report on Expert Discussion**

16:15

Presentation of outcome of expert discussion   
*Eric Van Cutsem, MD, PhD, Josep Tabernero, MD, PhD, Mario Dicato, MD*